SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Novartis
NVS 123.79+1.0%Oct 31 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Tom Wilkes who wrote (233)9/10/1998 8:02:00 AM
From: Anthony Wong  Read Replies (1) of 296
 
Novartis, the world's third-biggest drugmaker, will discuss
the benefits of Miacalcic, an injected or nasal spray drug used
to treat osteoporosis. Miacalcic is Novartis' tenth-biggest
selling drug, generating 224 million Swiss francs ($158 million)
in sales in the first half of 1998, a 26 percent rise.

Novartis Study

Novartis spokesman Mark Hill said his company on Sept. 14
will present four-year data from a study expected to last five
years aimed at demonstrating the ability of Miacalcic, a
synthetic salmon calcitonin, in preventing bone fractures in post-
menopausal women. Miacalcic is the second biggest prescribed drug
for osteoporosis in the U.S. after Fosamax, according to IMS
Health, a market research firm.

From an updated Bloomberg article September 10, 1998, 6:16 a.m. ET
quote.bloomberg.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News